Results 11 to 20 of about 590 (119)

Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab [PDF]

Dermatology Practical & Conceptual
Introduction: The advent of biotechnological drugs has significantly changed the management of atopic dermatitis (AD) and the approach to the moderate-to-severe form of this chronic relapsing disease.
Annunziata Dattola, Martina Tolone, Emanuele Amore, Luigi Bennardo, Simone Amato, Teresa Grieco, Antonio Giovanni Richetta, Giovanni Pellacani, Nevena Skroza, Steven Paul Nisticò   +9 more
doaj   +4 more sources

Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial

Dermatology and Therapy
Introduction Tralokinumab is approved for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 12 years. Here, we examined clinical laboratory parameters in adolescents with moderate-to-severe AD who were treated with ...
Amy S. Paller, Michael J. Cork, H. Chih-ho Hong, Weily Soong, Shannon K. R. Schneider, Hannah Lo, Frank Vinther, Patrick Thøgersen, Andreas Wollenberg   +8 more
doaj   +2 more sources

Longitudinal Proteomic Signatures of Dupilumab and Tralokinumab Treated Atopic Dermatitis Patients

Clinical and Translational Allergy
Background Atopic dermatitis (AD) is a chronic inflammatory disease driven by Type 2 (Th2) inflammation. Dupilumab (anti‐IL‐4Rα) and tralokinumab (anti‐IL‐13) are effective biologic therapies, but a direct comparison of their longitudinal effects on the ...
Wojciech Francuzik, Kristijan Pažur, Margitta Worm   +2 more
doaj   +2 more sources

Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data [PDF]

Clinical, Cosmetic and Investigational Dermatology, 2022
Katherine A Kelly,1 Patrick O Perche,1 Steven R Feldman1– 4 1Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC ...
Kelly KA, Perche PO, Feldman SR
doaj   +2 more sources

Real‐World Efficacy and Systemic Immune Modulation Upon Tralokinumab Treatment in Atopic Dermatitis

Clinical and Translational Allergy
Background Tralokinumab, an interleukin‐13 (IL‐13) monoclonal antibody, has shown clinical efficacy in randomized trials for moderate‐to‐severe atopic dermatitis (AD).
Meslina Almaci, Philipp Globig, Davender Redhu, Margitta Worm   +3 more
doaj   +2 more sources

Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals [PDF]

Journal of Dermatological Treatment
Background Genital involvement in atopic dermatitis(AD) can have a significant impact on the patient’s quality of life. However, inspection of genital areas is not usually conducted during routine examination and patients may be reluctant to inform the ...
Giovanni Paolino, Alessandra Narcisi, Andrea Carugno, Piergiorgio Malagoli, Matteo R. Di Nicola, Antonio Foti, Vittoria G. Bianchi, Andrea Gustavo Locatelli, Paolo Sena, Antonio Costanzo, Santo R. Mercuri, Mario Valenti   +11 more
doaj   +4 more sources

Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study [PDF]

, 2023
Background: Tralokinumab is a human monoclonal antibody targeting interleukin-13 that is approved for the treatment of moderate-severe atopic dermatitis.
Maurelli M., Munera Campos M., Peris K., Marzano A. V., Ortoncelli M., Bianchi L., Chiricozzi A., Seremet T., De Simone C., Balato A., Ferrucci S. M., Gkalpakiotis S., Di Nardo L., Carrascosa J. M., Caldarola G., Torres T., Ribero S., Argenziano G., Gori N., Galluzzo M., Girolomoni G., Ippoliti E., Conrad C.   +22 more
core   +4 more sources

Association of Tralokinumab and Adalimumab: Good Tolerance and Efficacy in a Case of Severe Atopic Dermatitis and Juvenile Idiopathic Arthritis

JEADV Clinical Practice
Atopic dermatitis is a chronic inflammatory and pruritic skin disease. The combination of tralokinumab with adalimumab in the treatment of inflammatory diseases had not yet been documented.
F. Rakotonandrasana, E. Puzenat, A. Ducournau, D. Popescu   +3 more
doaj   +2 more sources

Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials [PDF]

, 2023
Two phase III trials, ECZTRA 1 and 2, confirmed the efficacy and safety of tralokinumab versus placebo in adults with moderate-to-severe atopic dermatitis (AD).
Eric L. Simpson, Katoh, Norito, Pink, Andrew E., Blauvelt, Andrew, Andreas Wollenberg, Andrew E. Pink, Margitta Worm, Simpson, Eric L., Wollenberg, Andreas, Pink, Andrew, April W. Armstrong, Melinda Gooderham, Ketty Peris, Armstrong, April, Ann-Marie Tindberg, Steffensen, Louise Abildgaard, Simpson, Eric, Worm, Margitta, Andrew Blauvelt, Norito Katoh, Mark, Thomas, Thomas Mark, Peris, Ketty, Gooderham, Melinda, Puig Sanz, Lluís, Sébastien Barbarot, Louise Abildgaard Steffensen, Barbarot, Sébastien, Armstrong, April W., Puig, Luis, Universitat Autònoma de Barcelona, Luis Puig, Tindberg, Ann-Marie   +32 more
core   +3 more sources

Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study [PDF]

Acta Dermato-Venereologica
Tralokinumab is a monoclonal antibody selectively targeting IL-13, approved for moderate-to-severe atopic dermatitis (AD), for which real-world data are scarce.
Laura Calabrese, Elisa Cinotti, Martina D’Onghia, Alessandra Cartocci, Pietro Rubegni, François Maccari , Claire Boulard, Ziad Reguiai, Pierre-André Becherel, Caroline Jacobzone, Edouard Begon, Charlotte Fite, Beatrice Walls, Anne Laure Liegeon, Josiane Parier, Guillaume Chaby, Jean-Luc Perrot   +16 more
doaj   +2 more sources